Inici › Malaltia cardiovascular › Nova York › Poughkeepsie
Assaigs clínics de Malaltia cardiovascular a Poughkeepsie, NY
6 estudis de Malaltia cardiovascular busquen participants en centres de Poughkeepsie i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
ReclutantFase 4
- Hudson Valley Cardiovascular Practice PC, Poughkeepsie
Product Surveillance Registry
ReclutantEstudi observacional
- Poughkeepsie, Poughkeepsie
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
ReclutantFase 3
- Clinical Trial Site, Poughkeepsie
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
ReclutantFase 3
- Research Site, Poughkeepsie
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
ReclutantFase 3
- Hudson Valley Cardiovascular Physicians PC, Poughkeepsie
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Reclutant
- Vassar Brothers- Hudson Valley Cardiovascular Practice, Poughkeepsie
Assaigs de Malaltia cardiovascular en altres ciutats
- Boston, MA37 estudis
- New York City, NY33 estudis
- Washington, DC29 estudis
- Houston, TX24 estudis
- Dallas, TX23 estudis
- Atlanta, GA22 estudis
- Cleveland, OH22 estudis
- Chicago, IL21 estudis
- Philadelphia, PA21 estudis
- Pittsburgh, PA20 estudis
- St. Louis, MO20 estudis
- San Francisco, CA18 estudis
Altres estudis a Poughkeepsie
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.